Indian pharmaceutical major Lupin Limited has received approval from the U.S. Food and Drug Administration for its generic version of a widely prescribed anti-seizure medication, reinforcing its strategic focus on complex generics in the United States. The regulatory clearance enables the company to market the product in the world’s largest pharmaceutical market, where demand for cost-effective neurological therapies remains robust. The approval is expected to bolster Lupin’s U.S. revenues and enhance its competitive positioning.